지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 대한외과학회 Annals of Surgical Treatment and Research Annals of Surgical Treatment and Research Vol.93 No.4
- 발행연도
- 2017.10
- 수록면
- 186 - 194 (9page)
이용수
초록· 키워드
오류제보하기
Purpose: Neoadjuvant treatment may provide improved survival outcomes for patients with borderline resectable pancreatic cancer (BRPC). The purpose of this study is to evaluate the clinical outcomes of neoadjuvant treatment and to identify prognostic factors.
Methods: Forty patients who met the National Comprehensive Cancer Network definition of BRPC and received neoadjuvant treatment followed by surgery between 2007 and 2015 were evaluated. Prospectively collected clinicopathological outcomes were analyzed retrospectively.
Results: The mean age was 61.7 years and the male-to-female ratio was 1.8:1. Twenty-six, 3, and 11 patients received gemcitabine-based chemotherapy, 5-fluorouracil, and FOLFIRINOX, respectively. The 2-year survival rate (2YSR) was 36.6% and the median overall survival (OS) was 20 months. Of the 40 patients, 34 patients underwent resection and the 2YSR was 41.2% while the 2YSR of patients who did not undergo resection was 16.7% (P = 0.011). The 2YSR was significantly higher in patients who had partial response compared to stable disease (60.6% vs. 24.3%, P = 0.038), in patients who did than did not show a CA 19-9 response after neoadjuvant treatment (40.5% vs. 0%, P = 0.039) and in patients who did than did not receive radiotherapy (50.8% vs. 25.3%, P = 0.036). Five patients had local recurrence and 17 patients had systemic recurrence with a median disease specific survival of 15 months.
Conclusion: Neoadjuvant treatment followed by resection is effective for BRPC. Pancreatectomy and neoadjuvant treatment response may affect survival. Effective systemic therapy is needed to improve long-term survival since systemic metastasis accounts for a high proportion of recurrence.
Methods: Forty patients who met the National Comprehensive Cancer Network definition of BRPC and received neoadjuvant treatment followed by surgery between 2007 and 2015 were evaluated. Prospectively collected clinicopathological outcomes were analyzed retrospectively.
Results: The mean age was 61.7 years and the male-to-female ratio was 1.8:1. Twenty-six, 3, and 11 patients received gemcitabine-based chemotherapy, 5-fluorouracil, and FOLFIRINOX, respectively. The 2-year survival rate (2YSR) was 36.6% and the median overall survival (OS) was 20 months. Of the 40 patients, 34 patients underwent resection and the 2YSR was 41.2% while the 2YSR of patients who did not undergo resection was 16.7% (P = 0.011). The 2YSR was significantly higher in patients who had partial response compared to stable disease (60.6% vs. 24.3%, P = 0.038), in patients who did than did not show a CA 19-9 response after neoadjuvant treatment (40.5% vs. 0%, P = 0.039) and in patients who did than did not receive radiotherapy (50.8% vs. 25.3%, P = 0.036). Five patients had local recurrence and 17 patients had systemic recurrence with a median disease specific survival of 15 months.
Conclusion: Neoadjuvant treatment followed by resection is effective for BRPC. Pancreatectomy and neoadjuvant treatment response may affect survival. Effective systemic therapy is needed to improve long-term survival since systemic metastasis accounts for a high proportion of recurrence.
목차
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
참고문헌 (24)
참고문헌 신청
[학술지(정기간행물)] - 오창모 / 2016 / Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2013 / Cancer Research and Treatment 48 (2) : 436 ~ 450
[학술지(정기간행물)] - Siegel RL / 2015 / Cancer statistics, 2015 / CA Cancer J Clin 65 : 5 ~ 29
[학술지(정기간행물)] - Katz MH / 2008 / Borderline resectable pancreatic cancer : the importance of this emerging stage of disease / J Am Coll Surg 206 : 833 ~ 846
[인터넷자원] - National Comprehensive Cancer Network. / / NCCN practice guidelines for pancreatic cancer, version 2. 2014
[학술지(정기간행물)] - Satoi S / 2009 / Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer / Pancreas 38 : 282 ~ 288
[학술지(정기간행물)] - Siegel RL / 2015 / Cancer statistics, 2015 / CA Cancer J Clin 65 : 5 ~ 29
[학술지(정기간행물)] - Katz MH / 2008 / Borderline resectable pancreatic cancer : the importance of this emerging stage of disease / J Am Coll Surg 206 : 833 ~ 846
[인터넷자원] - National Comprehensive Cancer Network. / / NCCN practice guidelines for pancreatic cancer, version 2. 2014
[학술지(정기간행물)] - Satoi S / 2009 / Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer / Pancreas 38 : 282 ~ 288
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Current status of neoadjuvant therapy for pancreas cancer
대한임상종양학회 학술대회지
2021 .06
-
Is Neoadjuvant Therapy Needed in Patients with Resectable Pancreatic Cancer?
Gut and Liver
2022 .01
-
Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX
Gut and Liver
2021 .01
-
Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades
Annals of Hepato-Biliary-Pancreatic Surgery
2021 .05
-
Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis
Gut and Liver
2022 .01
-
Radiological response pattern and patient survival in patients undergoing neoadjuvant chemotherapy
대한외과학회 학술대회 초록집
2019 .10
-
Modifications to Treatment Plan of Rectal Cancer in Response to COVID-19 at the Philippine General Hospital
Annals of Coloproctology
2021 .08
-
The Role of Neoadjuvant Treatment in Resectable Pancreatic Cancer
대한외과학회 학술대회 초록집
2019 .10
-
Great Debates: Which is the Best? Resectable pancreatic cancer: Neoadjuvant treatment first
대한임상종양학회 학술대회지
2019 .02
-
Predictive and Prognostic Roles of Pathological Indicators for Patients with Breast Cancer on Neoadjuvant Chemotherapy
Journal of Breast Cancer
2019 .01
-
Corrigendum to: Is Neoadjuvant Therapy Needed in Patients with Resectable Pancreatic Cancer?
Gut and Liver
2023 .03
-
Recent treatment patterns and survival outcomes in pancreatic cancer according to clinical stage based on single-center large-cohort data
Annals of Hepato-Biliary-Pancreatic Surgery
2018 .11
-
Management of inoperable endometrial cancer
Obstetrics & Gynecology Science
2022 .07
-
Survival improvement in locally advanced pancreatic cancer after FOLFIRINOX neoadjuvant treatment and conversion surgery
Annals of Hepato-Biliary-Pancreatic Surgery
2021 .12
-
Role of Neoadjuvant Chemotherapy in the Management of Advanced Ovarian Cancer
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Clinical characteristics of rectal cancer patients with neoadjuvant chemoradiotherapy: a nationwide population-based cohort study in South Korea
Annals of Surgical Treatment and Research
2021 .05
-
Conventional and volumetric parameters of positron emission tomography: Can it be prognostic values in pancreatic cancer patients who underwent surgical resection after neoadjuvant treatment?
Annals of Hepato-Biliary-Pancreatic Surgery
2022 .12
-
Pancreatectomy following neoadjuvant treatment can improve oncologic outcome in high metabolic active resectable pancreatic cancer
Annals of Hepato-Biliary-Pancreatic Surgery
2022 .12
-
What Should We Do, If We Cannot Find The Tumor after Neoadjuvant Therapy?
대한외과학회 학술대회 초록집
2019 .10
-
Recent Advances in the Neoadjuvant Treatment of Breast Cancer
Journal of Breast Cancer
2017 .01
이 논문의 저자 정보
이 논문과 함께 이용한 논문
Factors influencing patterns of recurrence following pancreaticoduodenectomy for patients with distal bile duct cancer and ampulla of Vater cancer
Do Hyeon Lee
,
Hyoung Joo Kim
,
Chan Woo Cho
외 2명
Annals of Hepato-Biliary-Pancreatic Surgery
2022
.05
췌장선암의 절제술후 재발에 관한 분석
박정익
,
김송철
,
문혜경
외 7명
대한외과학회 학술대회 초록집
2004
.05
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2018-514-001328145